HRP20171875T1 - C-19 steroidi, namijenjeni inhibiranju neovaskulariziranja - Google Patents
C-19 steroidi, namijenjeni inhibiranju neovaskulariziranja Download PDFInfo
- Publication number
- HRP20171875T1 HRP20171875T1 HRP20171875TT HRP20171875T HRP20171875T1 HR P20171875 T1 HRP20171875 T1 HR P20171875T1 HR P20171875T T HRP20171875T T HR P20171875TT HR P20171875 T HRP20171875 T HR P20171875T HR P20171875 T1 HRP20171875 T1 HR P20171875T1
- Authority
- HR
- Croatia
- Prior art keywords
- hydrogen
- alkyl
- intended
- compound
- double bond
- Prior art date
Links
- 206010029113 Neovascularisation Diseases 0.000 title claims 2
- 230000002401 inhibitory effect Effects 0.000 title claims 2
- -1 C-19 steroids Chemical class 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 18
- 239000001257 hydrogen Substances 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 13
- 125000000217 alkyl group Chemical group 0.000 claims 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 9
- 150000002431 hydrogen Chemical class 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 150000002148 esters Chemical class 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 238000011282 treatment Methods 0.000 claims 6
- BQOIJSIMMIDHMO-FBPKJDBXSA-N 4-Hydroxytestosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1O BQOIJSIMMIDHMO-FBPKJDBXSA-N 0.000 claims 4
- 108091008605 VEGF receptors Proteins 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- KPPVNWGJXFMGAM-UUILKARUSA-N (e)-2-methyl-1-(6-methyl-3,4-dihydro-2h-quinolin-1-yl)but-2-en-1-one Chemical compound CC1=CC=C2N(C(=O)C(/C)=C/C)CCCC2=C1 KPPVNWGJXFMGAM-UUILKARUSA-N 0.000 claims 3
- 125000006539 C12 alkyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 3
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 3
- 125000002252 acyl group Chemical group 0.000 claims 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 3
- 230000004663 cell proliferation Effects 0.000 claims 3
- 238000010511 deprotection reaction Methods 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 238000011321 prophylaxis Methods 0.000 claims 3
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 2
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims 2
- 150000001241 acetals Chemical class 0.000 claims 2
- 210000002889 endothelial cell Anatomy 0.000 claims 2
- 150000002170 ethers Chemical class 0.000 claims 2
- 201000011066 hemangioma Diseases 0.000 claims 2
- 230000004968 inflammatory condition Effects 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102100032528 C-type lectin domain family 11 member A Human genes 0.000 claims 1
- 101710167766 C-type lectin domain family 11 member A Proteins 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 108091008794 FGF receptors Proteins 0.000 claims 1
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 108010002386 Interleukin-3 Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 102100020880 Kit ligand Human genes 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 201000009053 Neurodermatitis Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000031481 Pathologic Constriction Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 108010068588 Platelet-Derived Growth Factor alpha Receptor Proteins 0.000 claims 1
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 108010039445 Stem Cell Factor Proteins 0.000 claims 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 claims 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004087 cornea Anatomy 0.000 claims 1
- 230000002500 effect on skin Effects 0.000 claims 1
- 230000010595 endothelial cell migration Effects 0.000 claims 1
- 210000003630 histaminocyte Anatomy 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 230000036244 malformation Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000002523 pancreas lymphoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 230000008439 repair process Effects 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 230000037390 scarring Effects 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 210000004872 soft tissue Anatomy 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 230000036262 stenosis Effects 0.000 claims 1
- 208000037804 stenosis Diseases 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 claims 1
- 230000003074 vasoproliferative effect Effects 0.000 claims 1
- 210000004127 vitreous body Anatomy 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14200543.8A EP3040075B1 (en) | 2014-12-30 | 2014-12-30 | C-19 steroids for inhibiting neovascularization |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171875T1 true HRP20171875T1 (hr) | 2018-01-26 |
Family
ID=52146363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171875TT HRP20171875T1 (hr) | 2014-12-30 | 2017-12-04 | C-19 steroidi, namijenjeni inhibiranju neovaskulariziranja |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10426785B2 (OSRAM) |
| EP (2) | EP3040075B1 (OSRAM) |
| JP (1) | JP6788592B2 (OSRAM) |
| KR (1) | KR102481553B1 (OSRAM) |
| CN (2) | CN107206010B (OSRAM) |
| CA (1) | CA2972324C (OSRAM) |
| DK (1) | DK3040075T3 (OSRAM) |
| EA (2) | EA202190993A3 (OSRAM) |
| ES (1) | ES2651442T3 (OSRAM) |
| HR (1) | HRP20171875T1 (OSRAM) |
| HU (1) | HUE037698T2 (OSRAM) |
| NO (1) | NO3040075T3 (OSRAM) |
| PL (1) | PL3040075T3 (OSRAM) |
| PT (1) | PT3040075T (OSRAM) |
| RS (1) | RS56621B1 (OSRAM) |
| SI (1) | SI3040075T1 (OSRAM) |
| WO (1) | WO2016107778A1 (OSRAM) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3632445A1 (en) * | 2018-10-04 | 2020-04-08 | Curadis GmbH | Combinations with a c-19 steroid for treating cancers |
| CN114149923B (zh) * | 2021-11-19 | 2024-03-08 | 大连理工大学 | 内皮细胞-平滑肌细胞共培养的单流道微芯片模型的构建方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5504074A (en) * | 1993-08-06 | 1996-04-02 | Children's Medical Center Corporation | Estrogenic compounds as anti-angiogenic agents |
| NZ621449A (en) * | 2003-05-30 | 2015-07-31 | Genentech Inc | Treatment with anti-vegf antibodies |
| EP1756139A4 (en) * | 2004-03-12 | 2009-07-29 | Entremed Inc | ANTI-ANGIOGENIC AGENTS |
| US20060264413A1 (en) * | 2005-04-18 | 2006-11-23 | Sri International | Method and composition for inhibiting cell proliferation and angiogenesis |
| EP1854465A1 (en) * | 2006-05-12 | 2007-11-14 | Alexander Tobias Teichmann | Use of 4,17 beta-dihydroxyandrost-4-ene-3-one for treating cancers |
| ES2547339T3 (es) * | 2007-11-13 | 2015-10-05 | Curadis Gmbh | Esteroides C-19 para usos terapéuticos específicos |
| CN101619089B (zh) * | 2009-07-28 | 2011-07-20 | 陈大刚 | 抗肿瘤药物cl168、其合成方法及应用 |
-
2014
- 2014-12-30 PT PT142005438T patent/PT3040075T/pt unknown
- 2014-12-30 SI SI201430519T patent/SI3040075T1/en unknown
- 2014-12-30 EP EP14200543.8A patent/EP3040075B1/en active Active
- 2014-12-30 ES ES14200543.8T patent/ES2651442T3/es active Active
- 2014-12-30 DK DK14200543.8T patent/DK3040075T3/en active
- 2014-12-30 PL PL14200543T patent/PL3040075T3/pl unknown
- 2014-12-30 HU HUE14200543A patent/HUE037698T2/hu unknown
- 2014-12-30 NO NO14200543A patent/NO3040075T3/no unknown
- 2014-12-30 RS RS20171258A patent/RS56621B1/sr unknown
-
2015
- 2015-12-21 CN CN201580071870.0A patent/CN107206010B/zh not_active Expired - Fee Related
- 2015-12-21 KR KR1020177018043A patent/KR102481553B1/ko active Active
- 2015-12-21 WO PCT/EP2015/080762 patent/WO2016107778A1/en not_active Ceased
- 2015-12-21 EA EA202190993A patent/EA202190993A3/ru unknown
- 2015-12-21 JP JP2017535799A patent/JP6788592B2/ja not_active Expired - Fee Related
- 2015-12-21 EP EP15817308.8A patent/EP3215161A1/en not_active Withdrawn
- 2015-12-21 US US15/535,461 patent/US10426785B2/en active Active
- 2015-12-21 CN CN202110416346.XA patent/CN113117089A/zh active Pending
- 2015-12-21 CA CA2972324A patent/CA2972324C/en active Active
- 2015-12-21 EA EA201791209A patent/EA039485B1/ru unknown
-
2017
- 2017-12-04 HR HRP20171875TT patent/HRP20171875T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR102481553B1 (ko) | 2022-12-26 |
| CN107206010B (zh) | 2021-12-21 |
| NO3040075T3 (OSRAM) | 2018-02-10 |
| KR20170100539A (ko) | 2017-09-04 |
| EP3215161A1 (en) | 2017-09-13 |
| EA039485B1 (ru) | 2022-02-01 |
| EA201791209A1 (ru) | 2017-11-30 |
| EA202190993A3 (ru) | 2021-10-29 |
| US10426785B2 (en) | 2019-10-01 |
| JP2018508474A (ja) | 2018-03-29 |
| CA2972324A1 (en) | 2016-07-07 |
| CN107206010A (zh) | 2017-09-26 |
| PL3040075T3 (pl) | 2018-03-30 |
| CA2972324C (en) | 2023-09-26 |
| PT3040075T (pt) | 2017-12-20 |
| RS56621B1 (sr) | 2018-03-30 |
| CN113117089A (zh) | 2021-07-16 |
| DK3040075T3 (en) | 2017-12-18 |
| EP3040075A1 (en) | 2016-07-06 |
| ES2651442T3 (es) | 2018-01-26 |
| EA202190993A2 (ru) | 2021-08-31 |
| JP6788592B2 (ja) | 2020-11-25 |
| US20170360804A1 (en) | 2017-12-21 |
| HUE037698T2 (hu) | 2018-09-28 |
| EP3040075B1 (en) | 2017-09-13 |
| WO2016107778A1 (en) | 2016-07-07 |
| SI3040075T1 (en) | 2018-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2023190748A5 (OSRAM) | ||
| HRP20171829T1 (hr) | 2-piridil supstituirani imidazoli kao terapijski inhibitori alk5 i/ili alk4 | |
| CA2985540C (en) | Use of nuc-1031 in the treatment of cancer | |
| JP6754071B2 (ja) | メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用 | |
| EA038030B1 (ru) | Противоопухолевая терапия | |
| JP6648160B2 (ja) | 血管擬態の阻害剤としての、アリール−キノリン誘導体の新規の使用 | |
| WO2018147275A1 (ja) | 腫瘍治療用医薬組成物 | |
| US20180085341A1 (en) | Methods for treating cancer | |
| US12252472B1 (en) | Barbituric acid derivatives, their preparation and use thereof as leukocyte transmigration inhibitors and for treating inflammatory diseases, autoimmune diseases and cancer | |
| WO2016127873A1 (zh) | 异硫氰酸酯类化合物及其应用 | |
| Dong et al. | “Attractive/adhesion force” dual-regulatory nanogels capable of CXCR4 antagonism and autophagy inhibition for the treatment of metastatic breast cancer | |
| JP2026053473A (ja) | 癌または炎症性疾患の治療のためのヘテロ二環式カルボキシ酸 | |
| WO2018213424A1 (en) | Methods for treating cancer | |
| CA2983011A1 (en) | Methods for treating cancer | |
| SI3040075T1 (en) | C-19 STEROIDS FOR INHIBITION OF NEVASCULARIZATION | |
| WO2016168858A1 (en) | Methods for treating cancer | |
| JP6952980B2 (ja) | 血管新生阻害薬 | |
| WO2021075559A1 (ja) | 癌関連線維芽細胞の細胞増殖阻害剤又は細胞死誘導剤 | |
| JP2022528454A (ja) | Ａ－ＮＯＲ－５αアンドロスタン薬物と抗がん薬物との併用 | |
| JP2018508474A5 (OSRAM) | ||
| CN104725291B (zh) | Xpo1蛋白抑制剂 | |
| AU2016309356B2 (en) | Tumor therapeutic agent | |
| EA046190B1 (ru) | Новое комбинированное решение для лечения рака, резистентного к химиотерапии | |
| Emmanouilides et al. | Preliminary experience with bevacizumab in combination with standard chemotherapeutic regimens in the treatment of non-small cell lung cancer: a retrospective study | |
| TH115885A (th) | สารรวมของคู่ควบแอนติบอดีต้าน her2-ยา และ สารเคมีบำบัด และวิธีการของการใช้ |